Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
arginine hydrochloride + trimetazidine hydrochloride
- Development stage
- Unknown
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Arginine hydrochloride + trimetazidine hydrochloride is a combination therapy being investigated by The First Affiliated Hospital of Zhengzhou University for the treatment of advanced hepatocellular carcinoma (HCC). Trimetazidine hydrochloride is a small molecule metabolic agent traditionally used for cardiac conditions that acts by inhibiting 3-ketoacyl-CoA thiolase, thereby blocking fatty acid oxidation. In this oncology context, it is repurposed to disrupt the energy metabolism of cancer cells. Arginine hydrochloride is used as a metabolic modulator targeting energy pathways to exploit the Warburg effect observed in hepatoma cells. The combination is currently being evaluated in Phase 3 clinical trials for patients with advanced HCC who have failed first-line systemic therapy.
- Other names
- Arginine hydrochloride combined with trimetazidine hydrochloride tablets
02
Targets
HADHB (Long-chain 3-ketoacyl-CoA thiolase)
Beyond the preview
Go deeper on arginine hydrochloride + trimetazidine hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on arginine hydrochloride + trimetazidine hydrochloride.